FILTER

FILTERED INTERVIEW RESULTS

Timothy J. Miller

PRESIDENT & CEO, FORGE BIOLOGICS
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."

Lesley Millar-Nicholson

DIRECTOR, MIT TECHNOLOGY LICENSING OFFICE
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."

Robert E. Landry

EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.

Donna LaVoie

PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.

Jeff Reingold

COO, CONTRACT PHARMACAL CORP
Contract Pharmacal Corp explains how it is intends to maintain its organic growth.

Dr. Trevor P. Castor

PRESIDENT & CEO, APHIOS
Aphios explains its developments in Critical Fluid Inactivation, cannabidiol in the area of cancer-induced peripheral neuropathic pain, and combination therapeutics and methods for the treatment of neurodegenerative diseases.

Dr. Josep Bassaganya-Riera

CHAIRMAN, PRESIDENT AND CEO, LANDOS BIOPHARMA
Landos Biopharma is rapidly developing into an integrated biotech company with a powerful R&D engine and a robust commercial arm.

Scott Bluestein

CEO & CIO, HERCULES CAPITAL
Hercules Capital explains why it is well positioned to benefit from a thriving life sciences and technology scene.

James Sapirstein

PRESIDENT & CEO, AZURRX BIOPHARMA
AzurRx Biopharma has benefitted from the availability of financing to expand its pipeline.

William H. Lewis

CHAIR & CEO, INSMED
2020 has been a transformative year for Insmed that is now undertaking three exciting programs for rare and serious diseases.

MACIG

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2022

PARTNER EVENTS